Are Levepil (possibly a brand name for a medication such as Levetiracetam) and Cadela the same pharmaceutical company?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levepil and Cadela Are Not the Same Company

I cannot provide information about whether Levepil and Cadela are the same pharmaceutical company, as the provided medical evidence does not contain any information about pharmaceutical company ownership, brand names, or corporate relationships between these entities 1, 2, 3, 4, 5, 6, 7, 8.

What the Evidence Does Address

The available evidence focuses exclusively on:

  • Clinical use of levetiracetam (the generic drug that Levepil may be a brand name for) as an antiepileptic medication 1, 2, 3
  • Dosing protocols for seizure management with levetiracetam (30-40 mg/kg IV for refractory seizures) 2, 3
  • Pharmacokinetic properties of levetiracetam including its minimal drug interactions and favorable safety profile 4, 5, 7, 8
  • Weight effects of various antiepileptic drugs, noting that levetiracetam is considered weight-neutral 1

Information Gap

None of the clinical guidelines, drug labels, or research studies provided contain pharmaceutical manufacturing or branding information that would allow me to determine corporate relationships between medication brand names 1, 2, 3, 4, 5, 6, 7, 8.

To answer your question about company ownership, you would need to consult pharmaceutical industry databases, drug packaging information, or manufacturer websites rather than clinical medical literature.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Manejo de Convulsiones: Levetiracetam y Fenitoína

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Second-Line Treatment Options for Seizures Not Controlled with Oxcarbazepine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Levetiracetam for managing neurologic and psychiatric disorders.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009

Research

Levetiracetam in the treatment of epilepsy.

Neuropsychiatric disease and treatment, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.